"Not So Different": OneOncology Gives a Closer Look at Its Biosimilar Adoption

This week on the podcast, we’re speaking with Jeffrey Patton, MD, chief executive officer of Tennessee Oncology, a partner practice of OneOncology, and the president of physician services for OneOncology. Patton shares with us the rationale for the adoption of biosimilars, how patients are responding, and lessons learned.

The question of whether anticancer biosimilars will achieve strong uptake in the United States, and whether they will produce much-needed cost savings, is one that has pervaded the conversation about US biosimilars for some time. Shortly after Amgen launched the first 2 such agents, biosimilar trastuzumab and bevacizumab, OneOncology, a group that comprises 4 large community oncology practices and 100 sites of care, announced that it had made those 2 biosimilars preferred agents.

This week on the podcast, we’re speaking with Jeffrey Patton, MD, chief executive officer of Tennessee Oncology, a partner practice of OneOncology, and the president of physician services for OneOncology. Patton shares with us the rationale for the adoption of biosimilars, how patients are responding, and lessons learned.

Learn more about OneOncology's biosimilar adoption here, and read more about Amgen's biosimilars, Mvasi and Kanjinti, here.